HALOZYME THERAPEUTICS, INC. Pre-Tax Income
HALOZYME THERAPEUTICS, INC. (HALO) reported Pre-Tax Income of $284.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-06
- HALOZYME THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was $284.90M, a 39.02% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was $180.33M, a 25.38% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$100.85M, a 156.59% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was $218.96M, a 32.58% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was $466.88M, a 16.20% decline from fiscal 2024.
- HALOZYME THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was $557.13M, a 59.94% increase from fiscal 2023.
- HALOZYME THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was $348.33M, a 39.94% increase from fiscal 2022.
- HALOZYME THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was $248.92M, a 0.16% increase from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $284.90M 10-Q · filed 2026-08-06 | $465.23M 10-Q · filed 2026-08-06 | $364.38M derived: sum of 3 quarters · filed 2026-08-06 | $583.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $180.33M 10-Q · filed 2026-05-11 | $79.48M derived: sum of 2 quarters · filed 2026-05-11 | $298.44M derived: sum of 3 quarters · filed 2026-05-11 | $503.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$100.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $118.11M derived: sum of 2 quarters · filed 2026-02-17 | $323.05M derived: sum of 3 quarters · filed 2026-08-06 | $466.88M 10-K · filed 2026-02-17 |
| 2025-09-30 | $218.96M 10-Q · filed 2025-11-03 | $423.90M derived: sum of 2 quarters · filed 2026-08-06 | $567.72M 10-Q · filed 2025-11-03 | $745.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $204.94M 10-Q · filed 2026-08-06 | $348.77M 10-Q · filed 2026-08-06 | $526.98M derived: sum of 3 quarters · filed 2026-08-06 | $692.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $143.83M 10-Q · filed 2026-05-11 | $322.04M derived: sum of 2 quarters · filed 2026-05-11 | $487.19M derived: sum of 3 quarters · filed 2026-05-11 | $604.93M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $178.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $343.36M derived: sum of 2 quarters · filed 2026-02-17 | $461.10M derived: sum of 3 quarters · filed 2026-02-17 | $557.13M 10-K · filed 2026-02-17 |
| 2024-09-30 | $165.15M 10-Q · filed 2025-11-03 | $282.89M derived: sum of 2 quarters · filed 2025-11-03 | $378.92M 10-Q · filed 2025-11-03 | $480.09M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $117.74M 10-Q · filed 2025-08-05 | $213.77M 10-Q · filed 2025-08-05 | $314.95M derived: sum of 3 quarters · filed 2026-02-17 | $416.71M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $96.03M 10-Q · filed 2025-05-06 | $197.20M derived: sum of 2 quarters · filed 2026-02-17 | $298.96M derived: sum of 3 quarters · filed 2026-02-17 | $392.12M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $101.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $202.94M derived: sum of 2 quarters · filed 2026-02-17 | $296.09M derived: sum of 3 quarters · filed 2026-02-17 | $348.33M 10-K · filed 2026-02-17 |
| 2023-09-30 | $101.76M 10-Q · filed 2024-10-31 | $194.92M derived: sum of 2 quarters · filed 2024-10-31 | $247.15M 10-Q · filed 2024-10-31 | $317.94M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $93.16M 10-Q · filed 2024-08-06 | $145.39M 10-Q · filed 2024-08-06 | $216.19M derived: sum of 3 quarters · filed 2025-02-18 | $289.89M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $52.24M 10-Q · filed 2024-05-07 | $123.03M derived: sum of 2 quarters · filed 2025-02-18 | $196.74M derived: sum of 3 quarters · filed 2025-02-18 | $226.75M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $70.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $144.50M derived: sum of 2 quarters · filed 2025-02-18 | $174.51M derived: sum of 3 quarters · filed 2025-02-18 | $248.92M 10-K · filed 2025-02-18 |
| 2022-09-30 | $73.71M 10-Q · filed 2023-11-06 | $103.72M derived: sum of 2 quarters · filed 2023-11-06 | $178.13M 10-Q · filed 2023-11-06 | $232.94M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $30.01M 10-Q · filed 2023-08-08 | $104.42M 10-Q · filed 2023-08-08 | $159.23M derived: sum of 3 quarters · filed 2024-02-20 | $233.34M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $74.41M 10-Q · filed 2023-05-09 | $129.22M derived: sum of 2 quarters · filed 2024-02-20 | $203.32M derived: sum of 3 quarters · filed 2024-02-20 | $294.84M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $54.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $128.92M derived: sum of 2 quarters · filed 2024-02-20 | $220.43M derived: sum of 3 quarters · filed 2024-02-20 | $248.52M 10-K · filed 2024-02-20 |
| 2021-09-30 | $74.11M 10-Q · filed 2022-11-08 | $165.62M derived: sum of 2 quarters · filed 2022-11-08 | $193.71M 10-Q · filed 2022-11-08 | $266.96M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $91.52M 10-Q · filed 2022-08-09 | $119.60M 10-Q · filed 2022-08-09 | $192.85M derived: sum of 3 quarters · filed 2023-02-21 | $229.12M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $28.09M 10-Q · filed 2022-05-10 | $101.33M derived: sum of 2 quarters · filed 2023-02-21 | $137.60M derived: sum of 3 quarters · filed 2023-02-21 | $163.48M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $73.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $109.52M derived: sum of 2 quarters · filed 2023-02-21 | $135.39M derived: sum of 3 quarters · filed 2023-02-21 | $129.30M 10-K · filed 2023-02-21 |
| 2020-09-30 | $36.27M 10-Q · filed 2021-11-02 | $62.15M derived: sum of 2 quarters · filed 2021-11-02 | $56.05M 10-Q · filed 2021-11-02 | $21.59M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $25.88M 10-Q · filed 2021-08-09 | $19.78M 10-Q · filed 2021-08-09 | -$14.68M derived: sum of 3 quarters · filed 2022-02-22 | -$39.68M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | -$6.09M 10-Q · filed 2021-05-10 | -$40.55M derived: sum of 2 quarters · filed 2022-02-22 | -$65.55M derived: sum of 3 quarters · filed 2022-02-22 | -$80.16M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | -$34.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | -$59.46M derived: sum of 2 quarters · filed 2022-02-22 | -$74.07M derived: sum of 3 quarters · filed 2022-02-22 | -$72.25M 10-K · filed 2022-02-22 |
| 2019-09-30 | -$25.00M 10-Q · filed 2020-11-02 | -$39.61M derived: sum of 2 quarters · filed 2020-11-02 | -$37.79M 10-Q · filed 2020-11-02 | -$39.60M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-06-30 | -$14.61M 10-Q · filed 2020-08-10 | -$12.79M 10-Q · filed 2020-08-10 | -$14.60M derived: sum of 3 quarters · filed 2021-02-23 | -$42.45M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-03-31 | $1.82M 10-Q · filed 2020-05-11 | $9.00K derived: sum of 2 quarters · filed 2021-02-23 | -$27.84M derived: sum of 3 quarters · filed 2021-02-23 | -$50.70M derived: sum of 4 quarters · filed 2021-02-23 |
| 2018-12-31 | -$1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | -$29.66M derived: sum of 2 quarters · filed 2021-02-23 | -$52.52M derived: sum of 3 quarters · filed 2021-02-23 | -$79.79M 10-K · filed 2021-02-23 |
| 2018-09-30 | -$27.85M 10-Q · filed 2019-11-12 | -$50.71M derived: sum of 2 quarters · filed 2019-11-12 | -$77.98M 10-Q · filed 2019-11-12 | $43.57M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | -$22.86M 10-Q · filed 2019-08-06 | -$50.13M 10-Q · filed 2019-08-06 | $71.42M derived: sum of 3 quarters · filed 2020-02-24 | $74.75M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-03-31 | -$27.27M 10-Q · filed 2019-05-07 | $94.28M derived: sum of 2 quarters · filed 2020-02-24 | $97.61M derived: sum of 3 quarters · filed 2020-02-24 | $67.02M derived: sum of 4 quarters · filed 2020-02-24 |
| 2017-12-31 | $121.55M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $124.88M derived: sum of 2 quarters · filed 2020-02-24 | $94.30M derived: sum of 3 quarters · filed 2020-02-24 | $61.61M 10-K · filed 2020-02-24 |
| 2017-09-30 | $3.33M 10-Q · filed 2018-11-06 | -$27.25M derived: sum of 2 quarters · filed 2018-11-06 | -$59.94M 10-Q · filed 2018-11-06 | -$87.75M derived: sum of 4 quarters · filed 2019-02-21 |
| 2017-06-30 | -$30.58M 10-Q · filed 2018-08-07 | -$63.27M 10-Q · filed 2018-08-07 | -$91.08M derived: sum of 3 quarters · filed 2019-02-21 | -$118.74M derived: sum of 4 quarters · filed 2019-02-21 |
| 2017-03-31 | -$32.69M 10-Q · filed 2018-05-10 | -$60.49M derived: sum of 2 quarters · filed 2019-02-21 | -$88.16M derived: sum of 3 quarters · filed 2019-02-21 | -$114.73M derived: sum of 4 quarters · filed 2019-02-21 |
| 2016-12-31 | -$27.81M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | -$55.47M derived: sum of 2 quarters · filed 2019-02-21 | -$82.05M derived: sum of 3 quarters · filed 2019-02-21 | -$101.86M 10-K · filed 2019-02-21 |
| 2016-09-30 | -$27.66M 10-Q · filed 2017-11-07 | -$54.24M derived: sum of 2 quarters · filed 2017-11-07 | -$74.05M 10-Q · filed 2017-11-07 | -$69.73M derived: sum of 4 quarters · filed 2018-02-20 |
| 2016-06-30 | -$26.57M 10-Q · filed 2017-08-08 | -$46.39M 10-Q · filed 2017-08-08 | -$42.07M derived: sum of 3 quarters · filed 2018-02-20 | -$66.53M derived: sum of 4 quarters · filed 2018-02-20 |
| 2016-03-31 | -$19.82M 10-Q · filed 2017-05-09 | -$15.50M derived: sum of 2 quarters · filed 2018-02-20 | -$39.96M derived: sum of 3 quarters · filed 2018-02-20 | -$36.94M derived: sum of 4 quarters · filed 2018-02-20 |
| 2015-12-31 | $4.32M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | -$20.14M derived: sum of 2 quarters · filed 2018-02-20 | -$17.12M derived: sum of 3 quarters · filed 2018-02-20 | -$32.23M 10-K · filed 2018-02-20 |
| 2015-09-30 | -$24.46M 10-Q · filed 2016-11-07 | -$21.44M derived: sum of 2 quarters · filed 2016-11-07 | -$36.55M 10-Q · filed 2016-11-07 | |
| 2015-06-30 | $3.02M 10-Q · filed 2016-08-09 | -$12.09M 10-Q · filed 2016-08-09 | ||
| 2014-12-31 | -$68.38M 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |